Eisai Co., Ltd. (ESALF)
OTCMKTS
· Delayed Price · Currency is USD
26.00
0.00 (0.00%)
May 16, 2025, 4:00 PM EDT
Eisai Revenue
In the fiscal year ending March 31, 2025, Eisai had annual revenue of 789.40B JPY with 6.42% growth. Eisai had revenue of 188.24B in the quarter ending March 31, 2025, a decrease of -1.19%.
Revenue
789.40B JPY
Revenue Growth
+6.42%
P/S Ratio
1.42
Revenue / Employee
71.33M JPY
Employees
11,067
Market Cap
7.51B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 789.40B | 47.65B | 6.42% |
Mar 31, 2024 | 741.75B | -2.65B | -0.36% |
Mar 31, 2023 | 744.40B | -11.82B | -1.56% |
Mar 31, 2022 | 756.23B | 110.28B | 17.07% |
Mar 31, 2021 | 645.94B | -49.68B | -7.14% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
BioStem Technologies | 332.45M |
Eisai News
- 4 days ago - Eisai Co., Ltd. (ESALF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Eisai Co., Ltd. 2024 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 5 days ago - Eisai GAAP EPS of ¥163.76, revenue of ¥789.4B; initiates FY outlook - Seeking Alpha
- 4 weeks ago - Europe Approves Eisai-Biogen's Alzheimer's Drug 'Under Strict Conditions' After Initial Negative Opinion - Benzinga
- 4 weeks ago - Biogen/ Eisai win EU approval for Alzheimer’s therapy - Seeking Alpha
- 4 weeks ago - EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease - Reuters
- 6 weeks ago - Japanese Stocks Rise With Market Focused on U.S. Trade News - Barron's
- 2 months ago - LEQEMBI Market Sales Reflect Growing Confidence in Disease-Modifying Alzheimer's Treatments| DelveInsight - Benzinga